Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 30,000 shares at $140.24 ($4.1M) on 2024-05-15, disclosed to the SEC on 2024-05-16.
Scheduled sale ($4.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $135.66 | 15,000 | $2.0M | 49.2% |
| 2 | $140.24 | 15,000 | $2.1M | 50.8% |
| Total | $137.95 avg | 30,000 | $4.1M | 100% |
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |